A look back: The Expert Briefing on 13 Nov 17, page-7

I know some here call us dreamers when thinking out loud about valuations, but our assumptions are based on recent deals in the USA for T-cell based drug developments.

Compared to the most bio-techs that got working / trailing just one drug IMU got 3+4.
While others have to prove what their tech is based on and if their drug works IMU is actually improving what's been confirmed for years.
1. The immune system is designed to kill cancer like any other disease.
2. In patients where the immune system is either suppressed or doesn't recognize the intruder it can be stimulated to start its actions.
3. Now comes the IMU part. Instead of just stimulating the T-cells, IMU' s tech stimulates the correct T-cell production by stimulating the B-cells. Long lasting and way more effective. And that have B and HerVaxx already proven compared to the relevant stages of development of Herceptin and Keytruda.

Therefore, our assumptions about
being successful, dividends and sp levels are not crazy expectations.

Just because Aussies aren't able to compare doesn't mean the sp level is correct. Correct, IMU has got no income yet, but its IP alone is worth at least 2 x 500m plus 200m for the 3 vaxx according to recent deals.

Again, those who call us dreamers, rampers, disillusioned - think about your state of mind when ignoring the obvious and PROVEN.

GLTA